Transforming growth factor (TGF)-β type i receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from peyronie's plaque

Journal of Sexual Medicine

Volumn 7, Issue 10, 2010, Pages 3385-3395

  Piao, Shuguang ^a   Choi, Min Ji ^a   Tumurbaatar, Munkhbayar ^a   Kim, Woo Jean ^a   Jin, Hai Rong ^a   Shin, Sun Hwa ^a   Tuvshintur, Buyankhuu ^a   Yin, Guo Nan ^a   Song, Jae Sook ^a   Kwon, Mi Hye ^a   Lee, Sang Jin ^b   Han, Jee Young ^a   Kim, Seong Jin ^c   Ryu, Ji Kan ^a   Suh, Jun Kyu ^a  

^a Inha University School of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

ALK5; Cell Culture; Peyronie's Disease; SKI2162; Transforming Growth Factor Beta

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SKI 2162; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INTRACELLULAR TRANSPORT; MALE; PEYRONIE DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; TUNICA ALBUGINEA; UROLOGIC SURGERY; WESTERN BLOTTING;

EID: 77957371280     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01753.x     Document Type: Article

References (26)

1. Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006, 49:987-97.
2. Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie's disease: A critical analysis. Eur Urol 2006, 50:235-48.
3. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391-4.
4. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158:2284-90.
5. Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, Weidner W, Eickelberg O. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007, 51:255-61.
6. Mulhall JP. Expanding the paradigm for plaque development in Peyronie's disease. Int J Impot Res 2003, 15(5):93-102. suppl
7. El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br J Urol 1998, 81:445-52.
8. Piao S, Ryu JK, Shin HY, Zhang LW, Song S, Han JY, Park SH, Kim JM, Kim IH, Kim SJ, Suh JK. Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: A useful model for the study of Peyronie's disease. Int J Androl 2008, 31:346-53.
9. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005, 313:943-51.
10. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005, 171:889-98.
11. de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A, Gellibert F, Huet S. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005, 145:166-77.
12. Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, Jin HR, Kim WJ, Han JY, Hong SS, Park SH, Lee SJ, Kim IH, Lee CR, Kim DK, Mamura M, Kim SJ, Suh JK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009, 6:1284-96.
13. Zhang LW, Piao S, Choi MJ, Shin HY, Jin HR, Kim WJ, Song SU, Han JY, Park SH, Mamura M, Kim SJ, Ryu JK, Suh JK. Role of increased penile expression of transforming growth factor-beta1 and activation of the Smad signaling pathway in erectile dysfunction in streptozotocin-induced diabetic rats. J Sex Med 2008, 5:2318-29.
14. Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC, Abdel-Mageed AB, Hellstrom WJ. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003, 24:239-45.
15. Fandel TM, Bella AJ, Lin G, Tantiwongse K, Lin CS, Pohl J, Lue TF. Intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med 2008, 5:1866-75.
16. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 2002, 14:397-405.
17. Hoodless PA, Haerry T, Abdollah S, Stapleton M, O'Connor MB, Attisano L, Wrana JL. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 1996, 85:489-500.
18. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000, 14:627-44.
19. Isono M, Chen S, Hong SW, Iglesias-de la Cruz MC, Ziyadeh FN. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002, 296:1356-65.
20. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001, 158:1653-63.
21. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003, 305:1002-7.
22. Macías-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996, 87:1215-24.
23. Inman GJ, Nicolas FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell 2002, 10:283-94.
24. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62:65-74.
25. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002, 62:58-64.
26. Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 2004, 50:4008-21.